Last reviewed · How we verify
LPV
LPV is a protease inhibitor that blocks HIV protease, preventing the maturation of HIV virions and reducing viral replication.
LPV is a protease inhibitor that blocks HIV protease, preventing the maturation of HIV virions and reducing viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, COVID-19 (investigational use in phase 3).
At a glance
| Generic name | LPV |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | HIV protease inhibitor |
| Target | HIV-1 protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Lopinavir (LPV) is a potent inhibitor of the HIV-1 protease enzyme, which is essential for cleaving viral polyproteins into functional components during HIV replication. By inhibiting this protease, LPV prevents the production of infectious viral particles, thereby suppressing HIV replication and reducing viral load in infected individuals. It is typically administered as a fixed-dose combination with ritonavir (a CYP3A4 inhibitor) to enhance lopinavir bioavailability.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
- COVID-19 (investigational use in phase 3)
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Headache
- Lipid abnormalities (elevated cholesterol/triglycerides)
- Hepatotoxicity
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Platform of Randomized Adaptive Clinical Trials in Critical Illness (NA)
- A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+ (NA)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LPV CI brief — competitive landscape report
- LPV updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI